Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Illumina, Inc. (ILMN) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance

Illumina, Inc.Trade
Tripadvisor Inc Common StockTrade

Price performance (Past 24H)

Key statistics

Illumina, Inc. vs Tripadvisor Inc Common Stock — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while Tripadvisor Inc Common Stock trades at $11.04 (market cap $1.26B). The key difference: Illumina, Inc. is far larger — about 23× Tripadvisor Inc Common Stock's market cap, and Illumina, Inc. is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.

ILMNTRIP
Market Cap
$28.96B$1.26B
Sector
HealthConsumer Cyclical
52-Week High
$205.10$19.14
52-Week Low
$91.00$9.24
Enterprise Value
$30.32B$1.31B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Illumina, Inc.

Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.

The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.

Tripadvisor Inc Common Stock

Tripadvisor (TRIP) trades at $10.78, up 3.45% today, but faces bearish technical signals with recent earnings misses. The company maintains strong gross margins at 92.11% but struggles with thin net income margins of 0.27%. Recent Q2 2026 results missed expectations, though the $700M sale of TheFork to American Express provides strategic focus and cash infusion. Analyst consensus is mixed with 62.5% hold ratings and a $13.71 price target suggesting 27% upside potential from current levels.

TRIP presents a turnaround opportunity with simplified operations post-TheFork sale and Viator's growth potential, but faces persistent search-related pressures and uneven travel demand. The stock trades at reasonable valuations (P/S 0.7x) but carries execution risks amid competitive threats. Cash flow trends show volatility, with negative net cash flow projected for 2026, requiring careful monitoring of the company's strategic execution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN

About Tripadvisor Inc Common Stock

TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).

Read more on TRIP